Jazz Pharmaceuticals plc (J7Z) - Total Liabilities

Latest as of September 2025: €7.40 Billion EUR ≈ $8.65 Billion USD

Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has total liabilities worth €7.40 Billion EUR (≈ $8.65 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Jazz Pharmaceuticals plc to assess how effectively this company generates cash.

Jazz Pharmaceuticals plc - Total Liabilities Trend (2013–2024)

This chart illustrates how Jazz Pharmaceuticals plc's total liabilities have evolved over time, based on quarterly financial data. Check Jazz Pharmaceuticals plc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Jazz Pharmaceuticals plc Competitors by Total Liabilities

The table below lists competitors of Jazz Pharmaceuticals plc ranked by their total liabilities.

Company Country Total Liabilities
Zhejiang Dahua Technology Co Ltd
SHE:002236
China CN¥13.12 Billion
Beijing YanDong MicroElectronic Co. Ltd. A
SHG:688172
China CN¥4.51 Billion
Acuity Brands Inc
NYSE:AYI
USA $1.86 Billion
Sofina Société Anonyme
BR:SOF
Belgium €725.79 Million
Baxter International Inc
NYSE:BAX
USA $13.95 Billion
Itissalat Al-Maghrib
PA:IAM
France €51.67 Billion
Petronas Gas Bhd
KLSE:6033
Malaysia RM5.04 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Jazz Pharmaceuticals plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Jazz Pharmaceuticals plc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.65 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.87 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.65 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Jazz Pharmaceuticals plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Jazz Pharmaceuticals plc (2013–2024)

The table below shows the annual total liabilities of Jazz Pharmaceuticals plc from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 €7.92 Billion
≈ $9.26 Billion
+3.42%
2023-12-31 €7.66 Billion
≈ $8.95 Billion
-1.20%
2022-12-31 €7.75 Billion
≈ $9.06 Billion
-7.01%
2021-12-31 €8.33 Billion
≈ $9.74 Billion
+189.74%
2020-12-31 €2.88 Billion
≈ $3.36 Billion
+18.46%
2019-12-31 €2.43 Billion
≈ $2.84 Billion
-0.74%
2018-12-31 €2.45 Billion
≈ $2.86 Billion
+1.47%
2017-12-31 €2.41 Billion
≈ $2.82 Billion
-17.53%
2016-12-31 €2.92 Billion
≈ $3.42 Billion
+68.57%
2015-12-31 €1.73 Billion
≈ $2.03 Billion
-11.88%
2014-12-31 €1.97 Billion
≈ $2.30 Billion
+108.74%
2013-12-31 €942.69 Million
≈ $1.10 Billion
--

About Jazz Pharmaceuticals plc

F:J7Z Germany Biotechnology
Market Cap
$12.24 Billion
€10.47 Billion EUR
Market Cap Rank
#2434 Global
#497 in Germany
Share Price
€172.35
Change (1 day)
+0.73%
52-Week Range
€86.80 - €174.05
All Time High
€174.05
About

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LG… Read more